Lihua Budde, MD
Hematology · Duarte, CANPI 1124030028
Payments from drug & device makers
Across 593 payments — averaging $36,326 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$15.6M
- AstraZeneca$1.6M
- Merck$1.2M
- F. Hoffmann-la Roche AG$1M
- Seagen Inc.$540K
- Amgen$345K
- plus $1.2M from 19 others
Across 50 payments — averaging $687.51 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$34K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 188 | $15,625,706 |
| AstraZeneca(2 entities) | 43 | $1,605,308 |
| Merck | 9 | $1,223,134 |
| F. Hoffmann-la Roche AG | 61 | $1,033,011 |
| Seagen Inc. | 7 | $539,638 |
| Amgen | 4 | $345,453 |
| Gilead(2 entities) | 52 | $333,459 |
| Acerta Pharma LLC | 2 | $274,631 |
| Pharmacyclics LLC, An Abbvie Company | 109 | $179,306 |
| Hoffmann-la Roche Limited | 7 | $155,184 |
| Pfizer | 11 | $110,823 |
| AbbVie | 40 | $86,113 |
| Astrazeneca UK Limited | 6 | $10,608 |
| ADC Therapeutics America, Inc. | 12 | $4,930 |
| Janssen Global Services, LLC | 2 | $3,108 |
| Genentech USA, Inc. | 7 | $2,925 |
| Regeneron | 7 | $2,687 |
| Beigene USA, Inc. | 4 | $2,067 |
| E.r. Squibb & Sons, L.L.C. | 3 | $1,769 |
| Novartis | 7 | $987 |
| Incyte Corporation | 5 | $288 |
| Genmab U.S., Inc. | 1 | $158 |
| Taiho Oncology, Inc. | 4 | $137 |
| Jazz Pharmaceuticals Inc. | 1 | $27 |
| Bristol Myers Squibb | 1 | $16 |
How this compares
$21,541,472 in reported general payments places this provider in the 95th percentile of 178 hematology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology in Duarte
- Alex HerreraDuarte$50.9M
- Tycel PhillipsDuarte$21.6M
- Tanya SiddiqiDuarte$18.8M
- Amrita KrishnanDuarte$14M
- Anthony SteinDuarte$12.1M
- Alexey DanilovDuarte$11.3M
- Vincent ChungDuarte$11.1M
- Vinod PullarkatDuarte$10M
- Ibrahim AldossDuarte$9.9M
- Haris AliDuarte$7.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.